Surgical Science Sweden AB (publ)
Surgical Science Sweden AB (publ) SUSRF Peers
See (SUSRF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUSRF | $15.10 | +0.00% | 770.5M | 52.07 | $0.29 | N/A |
| PMCUF | $185.40 | +0.22% | 19.4B | 303.93 | $0.61 | +0.16% |
| MTHRF | $13.65 | +0.00% | 9.3B | 33.29 | $0.41 | +1.03% |
| MTHRY | $6.67 | -0.30% | 9.1B | 31.90 | $0.21 | N/A |
| PANHF | $0.91 | +0.00% | 2B | 90.90 | $0.01 | +137.13% |
| PIAHY | $2.29 | +0.00% | 1.2B | 114.50 | $0.02 | +108.54% |
| CMPVF | $23.75 | -0.44% | 1.2B | 40.95 | $0.58 | +4.21% |
| CMPUY | $23.00 | -7.26% | 1.2B | 38.98 | $0.59 | N/A |
| RSLBF | $32.05 | +0.00% | 1.1B | 47.84 | $0.67 | +0.98% |
| CRWRF | $29.25 | +0.00% | 1B | 69.64 | $0.42 | +1.29% |
Stock Comparison
SUSRF vs PMCUF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PMCUF has a market cap of 19.4B. Regarding current trading prices, SUSRF is priced at $15.10, while PMCUF trades at $185.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PMCUF's P/E ratio is 303.93. In terms of profitability, SUSRF's ROE is +0.03%, compared to PMCUF's ROE of +0.48%. Regarding short-term risk, SUSRF is more volatile compared to PMCUF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MTHRF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MTHRF has a market cap of 9.3B. Regarding current trading prices, SUSRF is priced at $15.10, while MTHRF trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MTHRF's P/E ratio is 33.29. In terms of profitability, SUSRF's ROE is +0.03%, compared to MTHRF's ROE of +0.09%. Regarding short-term risk, SUSRF is less volatile compared to MTHRF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MTHRY Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MTHRY has a market cap of 9.1B. Regarding current trading prices, SUSRF is priced at $15.10, while MTHRY trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MTHRY's P/E ratio is 31.90. In terms of profitability, SUSRF's ROE is +0.03%, compared to MTHRY's ROE of +0.09%. Regarding short-term risk, SUSRF is more volatile compared to MTHRY. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs PANHF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PANHF has a market cap of 2B. Regarding current trading prices, SUSRF is priced at $15.10, while PANHF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PANHF's P/E ratio is 90.90. In terms of profitability, SUSRF's ROE is +0.03%, compared to PANHF's ROE of -0.00%. Regarding short-term risk, SUSRF is more volatile compared to PANHF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs PIAHY Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PIAHY has a market cap of 1.2B. Regarding current trading prices, SUSRF is priced at $15.10, while PIAHY trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PIAHY's P/E ratio is 114.50. In terms of profitability, SUSRF's ROE is +0.03%, compared to PIAHY's ROE of -0.00%. Regarding short-term risk, SUSRF is more volatile compared to PIAHY. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CMPVF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CMPVF has a market cap of 1.2B. Regarding current trading prices, SUSRF is priced at $15.10, while CMPVF trades at $23.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CMPVF's P/E ratio is 40.95. In terms of profitability, SUSRF's ROE is +0.03%, compared to CMPVF's ROE of +0.04%. Regarding short-term risk, SUSRF is more volatile compared to CMPVF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CMPUY Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CMPUY has a market cap of 1.2B. Regarding current trading prices, SUSRF is priced at $15.10, while CMPUY trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CMPUY's P/E ratio is 38.98. In terms of profitability, SUSRF's ROE is +0.03%, compared to CMPUY's ROE of +0.04%. Regarding short-term risk, SUSRF is more volatile compared to CMPUY. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs RSLBF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, RSLBF has a market cap of 1.1B. Regarding current trading prices, SUSRF is priced at $15.10, while RSLBF trades at $32.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas RSLBF's P/E ratio is 47.84. In terms of profitability, SUSRF's ROE is +0.03%, compared to RSLBF's ROE of +0.26%. Regarding short-term risk, SUSRF is more volatile compared to RSLBF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CRWRF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CRWRF has a market cap of 1B. Regarding current trading prices, SUSRF is priced at $15.10, while CRWRF trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CRWRF's P/E ratio is 69.64. In terms of profitability, SUSRF's ROE is +0.03%, compared to CRWRF's ROE of +0.04%. Regarding short-term risk, SUSRF is less volatile compared to CRWRF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs SMSZF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, SMSZF has a market cap of 727.3M. Regarding current trading prices, SUSRF is priced at $15.10, while SMSZF trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas SMSZF's P/E ratio is 17.47. In terms of profitability, SUSRF's ROE is +0.03%, compared to SMSZF's ROE of +0.20%. Regarding short-term risk, SUSRF is more volatile compared to SMSZF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs VHIBF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, VHIBF has a market cap of 433.8M. Regarding current trading prices, SUSRF is priced at $15.10, while VHIBF trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas VHIBF's P/E ratio is 267.83. In terms of profitability, SUSRF's ROE is +0.03%, compared to VHIBF's ROE of +0.02%. Regarding short-term risk, SUSRF is more volatile compared to VHIBF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs KSIOF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, KSIOF has a market cap of 412.9M. Regarding current trading prices, SUSRF is priced at $15.10, while KSIOF trades at $4.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas KSIOF's P/E ratio is -218.70. In terms of profitability, SUSRF's ROE is +0.03%, compared to KSIOF's ROE of -0.05%. Regarding short-term risk, SUSRF is more volatile compared to KSIOF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs SMDCF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, SMDCF has a market cap of 280.9M. Regarding current trading prices, SUSRF is priced at $15.10, while SMDCF trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas SMDCF's P/E ratio is -17.32. In terms of profitability, SUSRF's ROE is +0.03%, compared to SMDCF's ROE of N/A. Regarding short-term risk, SUSRF is more volatile compared to SMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs DLHTF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, DLHTF has a market cap of 254.8M. Regarding current trading prices, SUSRF is priced at $15.10, while DLHTF trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas DLHTF's P/E ratio is -17.24. In terms of profitability, SUSRF's ROE is +0.03%, compared to DLHTF's ROE of -0.24%. Regarding short-term risk, SUSRF is more volatile compared to DLHTF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs COGZF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, COGZF has a market cap of 202.7M. Regarding current trading prices, SUSRF is priced at $15.10, while COGZF trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas COGZF's P/E ratio is 30.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to COGZF's ROE of +0.17%. Regarding short-term risk, SUSRF is more volatile compared to COGZF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs VPAHF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, VPAHF has a market cap of 188.2M. Regarding current trading prices, SUSRF is priced at $15.10, while VPAHF trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas VPAHF's P/E ratio is -37.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to VPAHF's ROE of -0.18%. Regarding short-term risk, SUSRF is more volatile compared to VPAHF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ACMLF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ACMLF has a market cap of 150.9M. Regarding current trading prices, SUSRF is priced at $15.10, while ACMLF trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ACMLF's P/E ratio is 35.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to ACMLF's ROE of +0.21%. Regarding short-term risk, SUSRF is less volatile compared to ACMLF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ONVVF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ONVVF has a market cap of 133.1M. Regarding current trading prices, SUSRF is priced at $15.10, while ONVVF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ONVVF's P/E ratio is -8.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to ONVVF's ROE of -0.97%. Regarding short-term risk, SUSRF is less volatile compared to ONVVF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CSAMF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CSAMF has a market cap of 98.8M. Regarding current trading prices, SUSRF is priced at $15.10, while CSAMF trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CSAMF's P/E ratio is -9.64. In terms of profitability, SUSRF's ROE is +0.03%, compared to CSAMF's ROE of -1.58%. Regarding short-term risk, SUSRF is more volatile compared to CSAMF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MDPEF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MDPEF has a market cap of 61.3M. Regarding current trading prices, SUSRF is priced at $15.10, while MDPEF trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MDPEF's P/E ratio is 6.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to MDPEF's ROE of N/A. Regarding short-term risk, SUSRF is less volatile compared to MDPEF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs HITC Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, HITC has a market cap of 52.8M. Regarding current trading prices, SUSRF is priced at $15.10, while HITC trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas HITC's P/E ratio is -14.75. In terms of profitability, SUSRF's ROE is +0.03%, compared to HITC's ROE of -1.29%. Regarding short-term risk, SUSRF is more volatile compared to HITC. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs RQHTF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, RQHTF has a market cap of 30.4M. Regarding current trading prices, SUSRF is priced at $15.10, while RQHTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas RQHTF's P/E ratio is -0.07. In terms of profitability, SUSRF's ROE is +0.03%, compared to RQHTF's ROE of -2.22%. Regarding short-term risk, SUSRF is more volatile compared to RQHTF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs RTNXF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, RTNXF has a market cap of 22.5M. Regarding current trading prices, SUSRF is priced at $15.10, while RTNXF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas RTNXF's P/E ratio is -0.33. In terms of profitability, SUSRF's ROE is +0.03%, compared to RTNXF's ROE of +2.93%. Regarding short-term risk, SUSRF is less volatile compared to RTNXF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs TREIF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, TREIF has a market cap of 22.1M. Regarding current trading prices, SUSRF is priced at $15.10, while TREIF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas TREIF's P/E ratio is -2.09. In terms of profitability, SUSRF's ROE is +0.03%, compared to TREIF's ROE of -11.21%. Regarding short-term risk, SUSRF is less volatile compared to TREIF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs VASO Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, VASO has a market cap of 22M. Regarding current trading prices, SUSRF is priced at $15.10, while VASO trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas VASO's P/E ratio is 12.51. In terms of profitability, SUSRF's ROE is +0.03%, compared to VASO's ROE of +0.04%. Regarding short-term risk, SUSRF is less volatile compared to VASO. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs HDSLF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, HDSLF has a market cap of 21.1M. Regarding current trading prices, SUSRF is priced at $15.10, while HDSLF trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas HDSLF's P/E ratio is -3.22. In terms of profitability, SUSRF's ROE is +0.03%, compared to HDSLF's ROE of -1.31%. Regarding short-term risk, SUSRF is more volatile compared to HDSLF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs THKKF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, THKKF has a market cap of 17.8M. Regarding current trading prices, SUSRF is priced at $15.10, while THKKF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas THKKF's P/E ratio is -1.51. In terms of profitability, SUSRF's ROE is +0.03%, compared to THKKF's ROE of -0.61%. Regarding short-term risk, SUSRF is more volatile compared to THKKF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs DGNOF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, DGNOF has a market cap of 15.7M. Regarding current trading prices, SUSRF is priced at $15.10, while DGNOF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas DGNOF's P/E ratio is -3.85. In terms of profitability, SUSRF's ROE is +0.03%, compared to DGNOF's ROE of +2.18%. Regarding short-term risk, SUSRF is less volatile compared to DGNOF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MDBIF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MDBIF has a market cap of 15.1M. Regarding current trading prices, SUSRF is priced at $15.10, while MDBIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MDBIF's P/E ratio is -2.43. In terms of profitability, SUSRF's ROE is +0.03%, compared to MDBIF's ROE of -0.14%. Regarding short-term risk, SUSRF is less volatile compared to MDBIF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MNNDF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MNNDF has a market cap of 14.3M. Regarding current trading prices, SUSRF is priced at $15.10, while MNNDF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MNNDF's P/E ratio is -1.48. In terms of profitability, SUSRF's ROE is +0.03%, compared to MNNDF's ROE of N/A. Regarding short-term risk, SUSRF is less volatile compared to MNNDF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs PBSV Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PBSV has a market cap of 13.8M. Regarding current trading prices, SUSRF is priced at $15.10, while PBSV trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PBSV's P/E ratio is -60.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to PBSV's ROE of -0.00%. Regarding short-term risk, SUSRF is more volatile compared to PBSV. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CRVW Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CRVW has a market cap of 11.7M. Regarding current trading prices, SUSRF is priced at $15.10, while CRVW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CRVW's P/E ratio is -2.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to CRVW's ROE of +0.16%. Regarding short-term risk, SUSRF is less volatile compared to CRVW. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs UDOCF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, UDOCF has a market cap of 10.7M. Regarding current trading prices, SUSRF is priced at $15.10, while UDOCF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas UDOCF's P/E ratio is -2.33. In terms of profitability, SUSRF's ROE is +0.03%, compared to UDOCF's ROE of +6.57%. Regarding short-term risk, SUSRF is less volatile compared to UDOCF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CDXFF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CDXFF has a market cap of 9.7M. Regarding current trading prices, SUSRF is priced at $15.10, while CDXFF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CDXFF's P/E ratio is -1.35. In terms of profitability, SUSRF's ROE is +0.03%, compared to CDXFF's ROE of +0.44%. Regarding short-term risk, SUSRF is more volatile compared to CDXFF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs HSCHF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, HSCHF has a market cap of 9.5M. Regarding current trading prices, SUSRF is priced at $15.10, while HSCHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas HSCHF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to HSCHF's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to HSCHF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs VYND Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, VYND has a market cap of 9.2M. Regarding current trading prices, SUSRF is priced at $15.10, while VYND trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas VYND's P/E ratio is -49.99. In terms of profitability, SUSRF's ROE is +0.03%, compared to VYND's ROE of +0.48%. Regarding short-term risk, SUSRF is more volatile compared to VYND. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs HBCNF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, HBCNF has a market cap of 8.4M. Regarding current trading prices, SUSRF is priced at $15.10, while HBCNF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas HBCNF's P/E ratio is -0.59. In terms of profitability, SUSRF's ROE is +0.03%, compared to HBCNF's ROE of -0.57%. Regarding short-term risk, SUSRF is less volatile compared to HBCNF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs SPLTF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, SPLTF has a market cap of 8M. Regarding current trading prices, SUSRF is priced at $15.10, while SPLTF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas SPLTF's P/E ratio is -2.60. In terms of profitability, SUSRF's ROE is +0.03%, compared to SPLTF's ROE of -6.63%. Regarding short-term risk, SUSRF is less volatile compared to SPLTF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs AIMLF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, AIMLF has a market cap of 7.5M. Regarding current trading prices, SUSRF is priced at $15.10, while AIMLF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas AIMLF's P/E ratio is -1.07. In terms of profitability, SUSRF's ROE is +0.03%, compared to AIMLF's ROE of -11.81%. Regarding short-term risk, SUSRF is less volatile compared to AIMLF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CRBKF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CRBKF has a market cap of 6.8M. Regarding current trading prices, SUSRF is priced at $15.10, while CRBKF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CRBKF's P/E ratio is -1.40. In terms of profitability, SUSRF's ROE is +0.03%, compared to CRBKF's ROE of +68.80%. Regarding short-term risk, SUSRF is more volatile compared to CRBKF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs EMOR Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, EMOR has a market cap of 6.6M. Regarding current trading prices, SUSRF is priced at $15.10, while EMOR trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas EMOR's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to EMOR's ROE of +0.28%. Regarding short-term risk, SUSRF is more volatile compared to EMOR. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs DOCRF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, DOCRF has a market cap of 6.2M. Regarding current trading prices, SUSRF is priced at $15.10, while DOCRF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas DOCRF's P/E ratio is -0.11. In terms of profitability, SUSRF's ROE is +0.03%, compared to DOCRF's ROE of -2.21%. Regarding short-term risk, SUSRF is more volatile compared to DOCRF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CNONF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CNONF has a market cap of 5M. Regarding current trading prices, SUSRF is priced at $15.10, while CNONF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CNONF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to CNONF's ROE of +1.60%. Regarding short-term risk, SUSRF is less volatile compared to CNONF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs RYAHF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, RYAHF has a market cap of 5M. Regarding current trading prices, SUSRF is priced at $15.10, while RYAHF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas RYAHF's P/E ratio is 0.25. In terms of profitability, SUSRF's ROE is +0.03%, compared to RYAHF's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to RYAHF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs IQAIF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, IQAIF has a market cap of 4.9M. Regarding current trading prices, SUSRF is priced at $15.10, while IQAIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas IQAIF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to IQAIF's ROE of -1.62%. Regarding short-term risk, SUSRF is more volatile compared to IQAIF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CMPD Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CMPD has a market cap of 4.4M. Regarding current trading prices, SUSRF is priced at $15.10, while CMPD trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CMPD's P/E ratio is -15.30. In terms of profitability, SUSRF's ROE is +0.03%, compared to CMPD's ROE of +0.07%. Regarding short-term risk, SUSRF is less volatile compared to CMPD. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs LVCE Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, LVCE has a market cap of 4.3M. Regarding current trading prices, SUSRF is priced at $15.10, while LVCE trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas LVCE's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to LVCE's ROE of N/A. Regarding short-term risk, SUSRF is more volatile compared to LVCE. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CBDS Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CBDS has a market cap of 4.3M. Regarding current trading prices, SUSRF is priced at $15.10, while CBDS trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CBDS's P/E ratio is -1.48. In terms of profitability, SUSRF's ROE is +0.03%, compared to CBDS's ROE of +1.55%. Regarding short-term risk, SUSRF is less volatile compared to CBDS. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CTVEF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CTVEF has a market cap of 3.9M. Regarding current trading prices, SUSRF is priced at $15.10, while CTVEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CTVEF's P/E ratio is -0.16. In terms of profitability, SUSRF's ROE is +0.03%, compared to CTVEF's ROE of +0.08%. Regarding short-term risk, SUSRF is less volatile compared to CTVEF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs EKGGF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, EKGGF has a market cap of 3.3M. Regarding current trading prices, SUSRF is priced at $15.10, while EKGGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas EKGGF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to EKGGF's ROE of +0.54%. Regarding short-term risk, SUSRF is more volatile compared to EKGGF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MITI Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MITI has a market cap of 3.2M. Regarding current trading prices, SUSRF is priced at $15.10, while MITI trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MITI's P/E ratio is -9.33. In terms of profitability, SUSRF's ROE is +0.03%, compared to MITI's ROE of -0.05%. Regarding short-term risk, SUSRF is less volatile compared to MITI. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CMHSF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CMHSF has a market cap of 2.2M. Regarding current trading prices, SUSRF is priced at $15.10, while CMHSF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CMHSF's P/E ratio is 1.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to CMHSF's ROE of +0.10%. Regarding short-term risk, SUSRF is less volatile compared to CMHSF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs EBYH Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, EBYH has a market cap of 2.1M. Regarding current trading prices, SUSRF is priced at $15.10, while EBYH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas EBYH's P/E ratio is -6.10. In terms of profitability, SUSRF's ROE is +0.03%, compared to EBYH's ROE of -0.03%. Regarding short-term risk, SUSRF is less volatile compared to EBYH. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs BNVIF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, BNVIF has a market cap of 1.7M. Regarding current trading prices, SUSRF is priced at $15.10, while BNVIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas BNVIF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to BNVIF's ROE of -4.34%. Regarding short-term risk, SUSRF is less volatile compared to BNVIF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MDXL Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MDXL has a market cap of 801K. Regarding current trading prices, SUSRF is priced at $15.10, while MDXL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MDXL's P/E ratio is -0.10. In terms of profitability, SUSRF's ROE is +0.03%, compared to MDXL's ROE of +0.90%. Regarding short-term risk, SUSRF is less volatile compared to MDXL. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs DTRK Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, DTRK has a market cap of 680.8K. Regarding current trading prices, SUSRF is priced at $15.10, while DTRK trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas DTRK's P/E ratio is -4.84. In terms of profitability, SUSRF's ROE is +0.03%, compared to DTRK's ROE of -9.79%. Regarding short-term risk, SUSRF is more volatile compared to DTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs NEWUF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, NEWUF has a market cap of 634.6K. Regarding current trading prices, SUSRF is priced at $15.10, while NEWUF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas NEWUF's P/E ratio is -0.03. In terms of profitability, SUSRF's ROE is +0.03%, compared to NEWUF's ROE of +0.67%. Regarding short-term risk, SUSRF is more volatile compared to NEWUF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs EVAHF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, EVAHF has a market cap of 557.6K. Regarding current trading prices, SUSRF is priced at $15.10, while EVAHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas EVAHF's P/E ratio is -4.80. In terms of profitability, SUSRF's ROE is +0.03%, compared to EVAHF's ROE of +0.29%. Regarding short-term risk, SUSRF is less volatile compared to EVAHF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MDRM Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MDRM has a market cap of 535.7K. Regarding current trading prices, SUSRF is priced at $15.10, while MDRM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MDRM's P/E ratio is -0.42. In terms of profitability, SUSRF's ROE is +0.03%, compared to MDRM's ROE of +0.42%. Regarding short-term risk, SUSRF is less volatile compared to MDRM. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MDNWF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MDNWF has a market cap of 517.3K. Regarding current trading prices, SUSRF is priced at $15.10, while MDNWF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MDNWF's P/E ratio is -0.02. In terms of profitability, SUSRF's ROE is +0.03%, compared to MDNWF's ROE of -1.53%. Regarding short-term risk, SUSRF is less volatile compared to MDNWF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CSOC Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CSOC has a market cap of 498.1K. Regarding current trading prices, SUSRF is priced at $15.10, while CSOC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CSOC's P/E ratio is 0.18. In terms of profitability, SUSRF's ROE is +0.03%, compared to CSOC's ROE of -2.38%. Regarding short-term risk, SUSRF is more volatile compared to CSOC. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs TSTTF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, TSTTF has a market cap of 461.3K. Regarding current trading prices, SUSRF is priced at $15.10, while TSTTF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas TSTTF's P/E ratio is -1.67. In terms of profitability, SUSRF's ROE is +0.03%, compared to TSTTF's ROE of +0.33%. Regarding short-term risk, SUSRF is less volatile compared to TSTTF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs NDATF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, NDATF has a market cap of 450.5K. Regarding current trading prices, SUSRF is priced at $15.10, while NDATF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas NDATF's P/E ratio is -0.55. In terms of profitability, SUSRF's ROE is +0.03%, compared to NDATF's ROE of -0.62%. Regarding short-term risk, SUSRF is more volatile compared to NDATF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ACHKF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ACHKF has a market cap of 377.4K. Regarding current trading prices, SUSRF is priced at $15.10, while ACHKF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ACHKF's P/E ratio is -0.05. In terms of profitability, SUSRF's ROE is +0.03%, compared to ACHKF's ROE of +2.16%. Regarding short-term risk, SUSRF is more volatile compared to ACHKF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs NHIQ Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, NHIQ has a market cap of 302.2K. Regarding current trading prices, SUSRF is priced at $15.10, while NHIQ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas NHIQ's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to NHIQ's ROE of +0.35%. Regarding short-term risk, SUSRF is less volatile compared to NHIQ. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs LFCOF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, LFCOF has a market cap of 282K. Regarding current trading prices, SUSRF is priced at $15.10, while LFCOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas LFCOF's P/E ratio is -0.04. In terms of profitability, SUSRF's ROE is +0.03%, compared to LFCOF's ROE of +8.70%. Regarding short-term risk, SUSRF is less volatile compared to LFCOF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ALDNF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ALDNF has a market cap of 160.4K. Regarding current trading prices, SUSRF is priced at $15.10, while ALDNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ALDNF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to ALDNF's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to ALDNF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs USPS Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, USPS has a market cap of 158.5K. Regarding current trading prices, SUSRF is priced at $15.10, while USPS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas USPS's P/E ratio is -1.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to USPS's ROE of -0.63%. Regarding short-term risk, SUSRF is more volatile compared to USPS. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs EMYSF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, EMYSF has a market cap of 151.7K. Regarding current trading prices, SUSRF is priced at $15.10, while EMYSF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas EMYSF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to EMYSF's ROE of +0.00%. Regarding short-term risk, SUSRF is less volatile compared to EMYSF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs DSOL Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, DSOL has a market cap of 88.9K. Regarding current trading prices, SUSRF is priced at $15.10, while DSOL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas DSOL's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to DSOL's ROE of +0.05%. Regarding short-term risk, SUSRF is more volatile compared to DSOL. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ICCO Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ICCO has a market cap of 71.7K. Regarding current trading prices, SUSRF is priced at $15.10, while ICCO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ICCO's P/E ratio is -0.40. In terms of profitability, SUSRF's ROE is +0.03%, compared to ICCO's ROE of +0.17%. Regarding short-term risk, SUSRF is less volatile compared to ICCO. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs REFG Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, REFG has a market cap of 60.8K. Regarding current trading prices, SUSRF is priced at $15.10, while REFG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas REFG's P/E ratio is -0.01. In terms of profitability, SUSRF's ROE is +0.03%, compared to REFG's ROE of +0.01%. Regarding short-term risk, SUSRF is more volatile compared to REFG. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs HDVY Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, HDVY has a market cap of 41.2K. Regarding current trading prices, SUSRF is priced at $15.10, while HDVY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas HDVY's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to HDVY's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to HDVY. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs IGRW Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, IGRW has a market cap of 39.8K. Regarding current trading prices, SUSRF is priced at $15.10, while IGRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas IGRW's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to IGRW's ROE of +7.88%. Regarding short-term risk, SUSRF is more volatile compared to IGRW. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs RVRC Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, RVRC has a market cap of 39.2K. Regarding current trading prices, SUSRF is priced at $15.10, while RVRC trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas RVRC's P/E ratio is -0.11. In terms of profitability, SUSRF's ROE is +0.03%, compared to RVRC's ROE of -0.29%. Regarding short-term risk, SUSRF is less volatile compared to RVRC. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs WMGR Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, WMGR has a market cap of 36.3K. Regarding current trading prices, SUSRF is priced at $15.10, while WMGR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas WMGR's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to WMGR's ROE of +0.00%. Regarding short-term risk, SUSRF is less volatile compared to WMGR. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs SSYNF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, SSYNF has a market cap of 33.3K. Regarding current trading prices, SUSRF is priced at $15.10, while SSYNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas SSYNF's P/E ratio is -0.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to SSYNF's ROE of N/A. Regarding short-term risk, SUSRF is more volatile compared to SSYNF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs SOFE Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, SOFE has a market cap of 31K. Regarding current trading prices, SUSRF is priced at $15.10, while SOFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas SOFE's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to SOFE's ROE of +0.52%. Regarding short-term risk, SUSRF is more volatile compared to SOFE. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs TTBLF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, TTBLF has a market cap of 26.7K. Regarding current trading prices, SUSRF is priced at $15.10, while TTBLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas TTBLF's P/E ratio is -0.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to TTBLF's ROE of -1.03%. Regarding short-term risk, SUSRF is less volatile compared to TTBLF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ORHB Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ORHB has a market cap of 25.6K. Regarding current trading prices, SUSRF is priced at $15.10, while ORHB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ORHB's P/E ratio is -0.01. In terms of profitability, SUSRF's ROE is +0.03%, compared to ORHB's ROE of +0.33%. Regarding short-term risk, SUSRF is more volatile compared to ORHB. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs EWLL Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, EWLL has a market cap of 18.5K. Regarding current trading prices, SUSRF is priced at $15.10, while EWLL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas EWLL's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to EWLL's ROE of +0.00%. Regarding short-term risk, SUSRF is less volatile compared to EWLL. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs NHEL Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, NHEL has a market cap of 16.2K. Regarding current trading prices, SUSRF is priced at $15.10, while NHEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas NHEL's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to NHEL's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to NHEL. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs FDBH Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, FDBH has a market cap of 15K. Regarding current trading prices, SUSRF is priced at $15.10, while FDBH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas FDBH's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to FDBH's ROE of +0.32%. Regarding short-term risk, SUSRF is more volatile compared to FDBH. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs HLTT Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, HLTT has a market cap of 10.7K. Regarding current trading prices, SUSRF is priced at $15.10, while HLTT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas HLTT's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to HLTT's ROE of +1789941.38%. Regarding short-term risk, SUSRF is more volatile compared to HLTT. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs PPJE Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PPJE has a market cap of 9.2K. Regarding current trading prices, SUSRF is priced at $15.10, while PPJE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PPJE's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to PPJE's ROE of +0.00%. Regarding short-term risk, SUSRF is less volatile compared to PPJE. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs CGNSF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, CGNSF has a market cap of 9K. Regarding current trading prices, SUSRF is priced at $15.10, while CGNSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas CGNSF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to CGNSF's ROE of +0.96%. Regarding short-term risk, SUSRF is more volatile compared to CGNSF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs MOSTQ Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, MOSTQ has a market cap of 8.5K. Regarding current trading prices, SUSRF is priced at $15.10, while MOSTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas MOSTQ's P/E ratio is -0.00. In terms of profitability, SUSRF's ROE is +0.03%, compared to MOSTQ's ROE of +2.26%. Regarding short-term risk, SUSRF is more volatile compared to MOSTQ. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ACNV Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ACNV has a market cap of 8.1K. Regarding current trading prices, SUSRF is priced at $15.10, while ACNV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ACNV's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to ACNV's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to ACNV. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs AHGIF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, AHGIF has a market cap of 7.8K. Regarding current trading prices, SUSRF is priced at $15.10, while AHGIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas AHGIF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to AHGIF's ROE of -2.79%. Regarding short-term risk, SUSRF is less volatile compared to AHGIF. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs NMXS Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, NMXS has a market cap of 3.8K. Regarding current trading prices, SUSRF is priced at $15.10, while NMXS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas NMXS's P/E ratio is -0.01. In terms of profitability, SUSRF's ROE is +0.03%, compared to NMXS's ROE of +1.59%. Regarding short-term risk, SUSRF is more volatile compared to NMXS. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs BBLNF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, BBLNF has a market cap of 2.6K. Regarding current trading prices, SUSRF is priced at $15.10, while BBLNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas BBLNF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to BBLNF's ROE of +1.06%. Regarding short-term risk, SUSRF is more volatile compared to BBLNF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs PCYS Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PCYS has a market cap of 1.1K. Regarding current trading prices, SUSRF is priced at $15.10, while PCYS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PCYS's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to PCYS's ROE of -2.71%. Regarding short-term risk, SUSRF is less volatile compared to PCYS. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs OLMM Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, OLMM has a market cap of 1K. Regarding current trading prices, SUSRF is priced at $15.10, while OLMM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas OLMM's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to OLMM's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to OLMM. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs PASO Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, PASO has a market cap of 741. Regarding current trading prices, SUSRF is priced at $15.10, while PASO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas PASO's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to PASO's ROE of +6.20%. Regarding short-term risk, SUSRF is less volatile compared to PASO. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs ETAOF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, ETAOF has a market cap of 512. Regarding current trading prices, SUSRF is priced at $15.10, while ETAOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas ETAOF's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to ETAOF's ROE of -13.69%. Regarding short-term risk, SUSRF is more volatile compared to ETAOF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs LGBI Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, LGBI has a market cap of 50. Regarding current trading prices, SUSRF is priced at $15.10, while LGBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas LGBI's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to LGBI's ROE of +0.00%. Regarding short-term risk, SUSRF is more volatile compared to LGBI. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs APYI Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, APYI has a market cap of 34. Regarding current trading prices, SUSRF is priced at $15.10, while APYI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas APYI's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to APYI's ROE of -0.60%. Regarding short-term risk, SUSRF is more volatile compared to APYI. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs VMCS Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, VMCS has a market cap of 0. Regarding current trading prices, SUSRF is priced at $15.10, while VMCS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas VMCS's P/E ratio is N/A. In terms of profitability, SUSRF's ROE is +0.03%, compared to VMCS's ROE of +3.10%. Regarding short-term risk, SUSRF is less volatile compared to VMCS. This indicates potentially lower risk in terms of short-term price fluctuations for SUSRF.
SUSRF vs WTEQF Comparison
SUSRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUSRF stands at 770.5M. In comparison, WTEQF has a market cap of 0. Regarding current trading prices, SUSRF is priced at $15.10, while WTEQF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUSRF currently has a P/E ratio of 52.07, whereas WTEQF's P/E ratio is 1.78. In terms of profitability, SUSRF's ROE is +0.03%, compared to WTEQF's ROE of N/A. Regarding short-term risk, SUSRF is more volatile compared to WTEQF. This indicates potentially higher risk in terms of short-term price fluctuations for SUSRF.